A Randomized, Prospective, Controlled Study of the Efficacy and Safety of Uralyt-U Combined With Febuxostat in the Treatment of Hyperuricemia With Uric Acid Stones

Inclusion Criteria:

• 18-70 years old, male, outpatient or inpatient;
• Acidic urinary stones
• Serum uric acid value ≥480 µmol / L;
• Other concomitant diseases (such as hypertension, hyperlipidemia, diabetes, etc.) are in a stable condition, and the dosage of other diseases is not changed during the test.
• eGFR≥30ml / min;

Exclusion Criteria:

• Pregnant or lactating women;
• Patients with acute or chronic renal failure (eGFR <30ml / min);
• Patients with severe liver dysfunction (ALT, AST≥70 IU);
• In patients with uncontrolled hypertension, systolic blood pressure ≥160 and / or diastolic blood pressure ≥110mmHg;
• In uncontrolled diabetic patients, fasting blood glucose is> 10mmol / L, and / or glycated hemoglobin is ≥9%;
• Patients that are taking atorvastatin, losartan, amlodipine, fenofibrate, pyrazinamide, tincture diuretics, thiazide diuretics, glucocorticoids, immunosuppressive agents and other drugs that affect uric acid excretion Drugs, those taking aspirin at a dose of> 325mg / day;
• Cancer patients